Keyphrases
Chemotherapy
100%
Advanced Prostate Cancer
100%
Evolving Roles
100%
Castration-resistant Prostate Cancer
75%
Androgen Deprivation Therapy
50%
Androgens
50%
Survival Benefit
50%
Docetaxel
25%
Disease Control
25%
Prostate Radiotherapy
25%
Taxanes
25%
Enzalutamide
25%
Testosterone
25%
Abiraterone
25%
Docetaxel Chemotherapy
25%
Cabazitaxel
25%
Overall Survival
25%
Early Use
25%
Treatment Landscape
25%
Cross-resistance
25%
New Treatment Options
25%
Surgical Castration
25%
New Hormonal Agents
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Prostate Cancer
100%
Androgen
57%
Docetaxel
28%
Enzalutamide
14%
Abiraterone
14%
Cabazitaxel
14%
Overall Survival
14%
Cross-Resistance
14%
Taxane
14%
Diseases
14%
Neuroscience
Androgen
100%
Prostate
75%
Docetaxel
50%
Hormonal Agents
25%
Taxane
25%
Cabazitaxel
25%
Enzalutamide
25%
Abiraterone
25%
Agricultural and Biological Sciences
Malignant Neoplasm
100%
Androgen
57%
Docetaxel
28%
Cross Resistance
14%
Enzalutamide
14%
Taxane
14%
Abiraterone
14%
Immunology and Microbiology
Prostate
100%
Cross-Resistance
33%
Overall Survival
33%